Napier KJ, Scheerer M, Misra S. Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol 2014; 6(5): 112-120 [PMID: 24834141 DOI: 10.4251/wjgo.v6.i5.112]
Corresponding Author of This Article
Subhasis Misra, MD, MS, FACCWS, FACS, Associate Professor, Division of Surgical Oncology, Chief of GastroIntestinal and Hepato-Pancreato-Biliary Surgery, Texas Tech University Health Science Center School of Medicine, 1400 S Coulter St.Amarillo, Amarillo, TX 79106, United States. subhasis.misra@ttuhsc.edu
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. May 15, 2014; 6(5): 112-120 Published online May 15, 2014. doi: 10.4251/wjgo.v6.i5.112
Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities
Kyle J Napier, Mary Scheerer, Subhasis Misra
Kyle J Napier, Mary Scheerer, Subhasis Misra, Department of Surgery, Texas Tech University Health Science Center School of Medicine, Amarillo, TX 79106, United States
Subhasis Misra, Division of Surgical Oncology, Chief of GastroIntestinal and Hepato-Pancreato-Biliary Surgery, Texas Tech University Health Science Center School of Medicine, Amarillo, TX 79106, United States
Author contributions: Napier KJ and Scheerer M contributed equally to the writing of this paper and should be deemed both first authors; Misra S was the senior author and guide for this paper.
Correspondence to: Subhasis Misra, MD, MS, FACCWS, FACS, Associate Professor, Division of Surgical Oncology, Chief of GastroIntestinal and Hepato-Pancreato-Biliary Surgery, Texas Tech University Health Science Center School of Medicine, 1400 S Coulter St.Amarillo, Amarillo, TX 79106, United States. subhasis.misra@ttuhsc.edu
Telephone: +1-806-3545563 Fax: +1-806-3545561
Received: November 17, 2013 Revised: December 31, 2013 Accepted: April 11, 2014 Published online: May 15, 2014
Core Tip
Core tip: Esophageal carcinoma is a serious malignancy with regards to mortality and prognosis, and is expected to increase in incidence over the next 10 years. Squamous cell carcinoma is the most common histological type of esophageal cancer worldwide but the incidence of esophageal adenocarcinoma has dramatically increased in the past 40 years. Esophageal cancer is staged according to the TNM system. Common imaging modalities used in staging include computed tomography, endoscopic ultrasound and positron emission tomography scans. Current treatment options include multimodality therapy. Including surgery, radiation and chemotherapy. Tumor markers of esophageal cancer are an advancing area of research that could potentially lead to earlier diagnosis.
